Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
As of today, Moderna(MRNA) shares are valued at $40.05. The company's market cap stands at 16.02B, with a P/E ratio of -5.02.
On 2026-02-12, Moderna(MRNA) stock traded between a low of $39.44 and a high of $40.88. Shares are currently priced at $40.05, which is +1.5% above the low and -2.0% below the high.
Moderna(MRNA) shares are trading with a volume of 2.11M, against a daily average of 10.8M.
In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.
In the last year, Moderna(MRNA) shares hit a 52-week high of $55.20 and a 52-week low of $22.28.
MRNA News
Mani Foroohar, an analyst from Leerink Partners, maintained the Sell rating on Moderna. The associated price target was lowered to $12.00. Mani Foroohar has gi...
FDA declined to review Moderna's application for its mRNA based flu vaccine, citing issues with clinical trial design. Moderna disputes the FDA's basis for ref...
Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research, overruled the agency’s reviewers in refusing to accept Moderna’s (MRNA) applic...
Analyst ratings
70%
of 27 ratingsMore MRNA News
Leerink lowered the firm’s price target on Moderna (MRNA) to $12 from $17 and keeps an Underperform rating on the shares. The firm notes that after the close, M...
The latest update is out from Moderna ( (MRNA) ). On February 10, 2026, Moderna disclosed that the U.S. Food and Drug Administration’s Center for Biologics Eva...
Moderna Inc. (NASDAQ:MRNA) stock fell Wednesday as the company faced a setback following a refusal-to-file letter from the U.S. Food and Drug Administration (FD...
Moderna (MRNA) stock plunged nearly 9% in after-hours trading on February 10 after the U.S. Food and Drug Administration (FDA) issued a “refusal-to-file” letter...
Moderna (MRNA) announced the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research has notified the company that it will not initiate...
Technology Moderna Takes It On The Chin After FDA Rejects Its Messenger-RNA-Based Flu Shot Licensing The Food and Drug Administration rejected Moderna's (MRNA)...
A researcher works in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. The Food and Drug Administration re...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.